Microvascular density is the clinical standard for evaluating tumor angiogenesis, which negatively affects the outcome of antitumor therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) [8]. This evidence concerns the gene EGFR and neoplasm.